12/17
06:30 am
afmd
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
High
Report
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
12/12
02:39 pm
afmd
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.
12/10
08:00 am
afmd
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
12/9
01:30 pm
afmd
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Low
Report
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
12/9
06:30 am
afmd
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
High
Report
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
12/8
12:00 pm
afmd
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Medium
Report
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
12/5
06:30 am
afmd
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Medium
Report
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
11/19
09:31 am
afmd
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/15
09:11 am
afmd
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "hold" rating on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "hold" rating on the stock.
11/15
08:02 am
afmd
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/14
06:30 am
afmd
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Low
Report
Affimed Reports Third Quarter 2024 Financial Results & Business Update
11/6
06:30 am
afmd
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Medium
Report
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
11/5
09:00 am
afmd
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
High
Report
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma